Sei Investments Co. Sells 41,390 Shares of IDEXX Laboratories, Inc. $IDXX

Sei Investments Co. decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 30.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 94,486 shares of the company’s stock after selling 41,390 shares during the period. Sei Investments Co. owned approximately 0.12% of IDEXX Laboratories worth $53,089,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Harbour Investments Inc. grew its stake in IDEXX Laboratories by 13.3% in the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after acquiring an additional 16 shares during the period. Rockland Trust Co. raised its position in shares of IDEXX Laboratories by 4.4% during the fourth quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after purchasing an additional 18 shares during the period. Prime Capital Investment Advisors LLC raised its position in shares of IDEXX Laboratories by 0.5% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock worth $2,654,000 after purchasing an additional 18 shares during the period. Pinnacle Associates Ltd. lifted its holdings in shares of IDEXX Laboratories by 1.5% during the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock valued at $830,000 after purchasing an additional 18 shares in the last quarter. Finally, Triad Wealth Partners LLC lifted its holdings in shares of IDEXX Laboratories by 3.1% during the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock valued at $337,000 after purchasing an additional 18 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on IDXX shares. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $544.32 on Friday. The firm’s 50 day moving average is $556.27 and its 200-day moving average is $595.41. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $42.94 billion, a PE ratio of 40.08, a price-to-earnings-growth ratio of 2.98 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $518.55 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the company posted $2.91 earnings per share. The firm’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.